All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What treatment would you suggest for high risk MDS patients not fit for chemotherapy or hematopoietic stem cell transplantation (HSCT)?

What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?

Brunner discusses the challenges associated with treatment for patients who are not fit for chemotherapy or HSCT. He goes on to discuss hypomethylating agent therapy, such as azacitidine and decitabine regimens, as well as talking about supportive care.

 

Share: